# Antibody Optimization Report Template

Use this template when generating the `antibody_optimization_report.md` output file. Each section corresponds to a workflow phase. Fill in data from tool results as analysis progresses.

---

## Report Header

```markdown
# Antibody Optimization Report: [ANTIBODY_NAME]

**Generated**: [Date] | **Target**: [Target Antigen] | **Status**: Complete

---

## Executive Summary

[Summary of optimization strategy, key improvements, and recommendations...]

**Top Candidate**: [Variant name]
- Humanization: 87% (from 62%)
- Affinity: 1.2 nM (7x improvement)
- Developability score: 82/100 (Tier 1)
- Immunogenicity: Low risk
- Manufacturing: Standard process

**Recommendation**: Advance to preclinical development
```

---

## Section 1: Input Characterization (Phase 1)

```markdown
## 1. Input Characterization

### 1.1 Sequence Information

| Property | Heavy Chain (VH) | Light Chain (VL) |
|----------|------------------|------------------|
| **Length** | 118 aa | 107 aa |
| **Species** | Mouse (Mus musculus) | Mouse (Mus musculus) |
| **Humanness** | 62% | 68% |
| **Closest human germline** | IGHV1-69*01 (87% identity) | IGKV1-39*01 (90% identity) |

### 1.2 CDR Annotation (IMGT Numbering)

**Heavy Chain**:
- FR1: 1-26, CDR-H1: 27-38, FR2: 39-55, CDR-H2: 56-65, FR3: 66-104, CDR-H3: 105-117, FR4: 118-128

**CDR Sequences**:
| CDR | Sequence | Length | Canonical Class |
|-----|----------|--------|-----------------|
| CDR-H1 | GYTFTSYYMH | 10 | H1-13-1 |
| CDR-H2 | GIIPIFGTANY | 11 | H2-10-1 |
| CDR-H3 | ARDDGSYSPFDYWG | 14 | - (unique) |
| CDR-L1 | RASQSISSYLN | 11 | L1-11-1 |
| CDR-L2 | AASSLQS | 7 | L2-8-1 |
| CDR-L3 | QQSYSTPLT | 9 | L3-9-cis7-1 |

### 1.3 Target Information

| Property | Value |
|----------|-------|
| **Target** | PD-L1 (Programmed death-ligand 1) |
| **UniProt** | Q9NZQ7 |
| **Function** | Immune checkpoint, inhibits T-cell activation |
| **Disease relevance** | Cancer immunotherapy target |

### 1.4 Clinical Precedents

**Approved antibodies targeting PD-L1**:
1. **Atezolizumab** (Tecentriq) - IgG1, approved 2016
2. **Durvalumab** (Imfinzi) - IgG1, approved 2017
3. **Avelumab** (Bavencio) - IgG1, approved 2017

**Key insights**: All approved anti-PD-L1 antibodies use human IgG1 scaffolds with effector function modifications.

*Source: TheraSAbDab, UniProt*
```

---

## Section 2: Humanization Strategy (Phase 2)

```markdown
## 2. Humanization Strategy

### 2.1 Framework Selection

**Selected Human Frameworks**:

| Chain | Germline | Identity | CDR Compatibility | Clinical Use | Score |
|-------|----------|----------|-------------------|--------------|-------|
| **VH** | IGHV1-69*01 | 87.2% | Excellent | 127 antibodies | 94/100 |
| **VL** | IGKV1-39*01 | 89.5% | Excellent | 89 antibodies | 92/100 |

**Rationale**:
- IGHV1-69*01: Most frequently used human germline in therapeutic antibodies
- High sequence identity minimizes risk of affinity loss
- Excellent CDR canonical class compatibility
- Proven clinical track record

### 2.2 CDR Grafting Design

**Grafting Strategy**: Direct CDR transfer with Vernier zone optimization

| Region | Source | Sequence | Rationale |
|--------|--------|----------|-----------|
| FR1 | IGHV1-69*01 | EVQLVQSGAEVKKPGA... | Human framework |
| CDR-H1 | Mouse | GYTFTSYYMH | Retain binding |
| FR2 | IGHV1-69*01 | VKWVRQAPGQGLE... | Human framework |
| CDR-H2 | Mouse | GIIPIFGTANY | Retain binding |
| FR3 | IGHV1-69*01 | RVTMTTDTSTSTYME... | Human framework |
| CDR-H3 | Mouse | ARDDGSYSPFDYWG | Retain binding |
| FR4 | IGHJ4*01 | WGQGTLVTVSS | Human framework |

### 2.3 Backmutation Analysis

**Identified Vernier Zone Residues** (may require backmutation):

| Position | Human | Mouse | Region | Impact | Priority |
|----------|-------|-------|--------|--------|----------|
| 27 | T | A | CDR-H1 boundary | CDR conformation | High |
| 48 | I | V | FR2 | VH-VL interface | High |
| 67 | A | S | FR3 | CDR-H2 support | Medium |
| 71 | R | K | FR3 | CDR-H2 support | Medium |
| 93 | A | T | FR3 | CDR-H3 base | Medium |

**Recommendation**: Test versions with/without backmutations at positions 27 and 48

### 2.4 Humanized Sequences

**Version 1: Full humanization** (no backmutations)
>VH_Humanized_v1 | 87% human framework

**Version 2: With key backmutations** (positions 27, 48)
>VH_Humanized_v2 | 85% human framework + backmutations

**Humanization Metrics**:
| Metric | Original (Mouse) | v1 (Full) | v2 (Backmut) |
|--------|------------------|-----------|--------------|
| Framework humanness | 62% | 87% | 85% |
| CDR preservation | 100% | 100% | 100% |
| Vernier zone match | Mouse | Human | Mixed |
| Predicted affinity | Baseline | 60-80% | 80-100% |

*Source: IMGT germline database, CDR analysis*
```

---

## Section 3: Structure Modeling (Phase 3)

```markdown
## 3. Structure Modeling & Analysis

### 3.1 AlphaFold Predictions

**Structure Quality**:

| Variant | Mean pLDDT | VH pLDDT | VL pLDDT | CDR pLDDT | Confidence |
|---------|------------|----------|----------|-----------|------------|
| Original (Mouse) | 89.2 | 91.4 | 88.7 | 85.3 | High |
| VH_Humanized_v1 | 87.8 | 89.6 | 88.2 | 83.1 | High |
| VH_Humanized_v2 | 88.9 | 90.8 | 88.5 | 84.8 | High |

### 3.2 CDR Conformation Analysis

| CDR | Length | Canonical Class | RMSD to Class | Status |
|-----|--------|-----------------|---------------|--------|
| CDR-H1 | 10 | H1-13-1 | 0.8 A | Maintained |
| CDR-H2 | 11 | H2-10-1 | 1.1 A | Maintained |
| CDR-H3 | 14 | Non-canonical | N/A | Unique structure |
| CDR-L1 | 11 | L1-11-1 | 0.9 A | Maintained |
| CDR-L2 | 7 | L2-8-1 | 0.7 A | Maintained |
| CDR-L3 | 9 | L3-9-cis7-1 | 1.0 A | Maintained |

### 3.3 Epitope Analysis

**Known Epitopes** (IEDB):
| Epitope | Sequence | Position | Binding Antibodies | Conservation |
|---------|----------|----------|-------------------|--------------|
| Epitope 1 | LQDAG...VPEPP | 19-113 | Durvalumab, Avelumab | 98% |
| Epitope 2 | FTVT...PGPN | 54-68 | Atezolizumab | 100% |

### 3.4 Structural Comparison

| Reference | PDB ID | VH RMSD | VL RMSD | CDR-H3 RMSD | Notes |
|-----------|--------|---------|---------|-------------|-------|
| Atezolizumab | 5X8L | 1.2 A | 1.4 A | 2.8 A | Similar approach angle |
| Durvalumab | 5X8M | 1.8 A | 1.5 A | 3.4 A | Different epitope |

*Source: AlphaFold, IEDB, SAbDab*
```

---

## Section 4: Affinity Optimization (Phase 4)

```markdown
## 4. Affinity Optimization

### 4.1 Current Affinity Assessment

| Property | Value | Method |
|----------|-------|--------|
| **Predicted KD** | 5.2 nM | Structure-based prediction |
| **Buried surface area** | 820 A2 | AlphaFold model |
| **Interface hotspots** | 6 residues | Energy decomposition |

### 4.2 Proposed Affinity Mutations

**High-Priority Mutations** (predicted >2x improvement):

| Position | Original | Mutant | Region | Predicted DDG | KD Fold | Rationale |
|----------|----------|--------|--------|---------------|---------|-----------|
| H100a | S | Y | CDR-H3 | -1.2 kcal/mol | 7.4x | Pi-stacking with target Phe |
| H52 | I | W | CDR-H2 | -0.9 kcal/mol | 4.8x | Increased hydrophobic contact |
| L91 | Q | E | CDR-L3 | -0.7 kcal/mol | 3.3x | Salt bridge with target Arg |

### 4.3 Combination Strategy

**Recommended Testing Order**:
1. Single mutants: H100aY, H52W, L91E
2. Double mutants: H100aY+H52W, H100aY+L91E
3. Triple mutant: H100aY+H52W+L91E (if additivity observed)

### 4.4 CDR Optimization Strategies

- **CDR-H3 Extension**: Add Gly-Tyr at C-terminus (+2-3x affinity)
- **Tyrosine Enrichment**: Tyr provides pi-stacking and H-bonds (+2-4x)
- **pH-Dependent Binding** (optional): Add His residues for tumor selectivity

*Source: In silico modeling, structural analysis*
```

---

## Section 5: Developability Assessment (Phase 5)

```markdown
## 5. Developability Assessment

### 5.1 Overall Developability Score

| Variant | Aggregation | PTM | Stability | Expression | Solubility | **Overall** | Tier |
|---------|-------------|-----|-----------|------------|------------|-------------|------|
| Original | 58 | 45 | 72 | 65 | 70 | **62** | T3 |
| Humanized_v1 | 72 | 55 | 75 | 78 | 75 | **71** | T2 |
| Humanized_v2 | 68 | 58 | 74 | 75 | 73 | **69** | T2 |
| Affinity_opt | 85 | 72 | 78 | 80 | 82 | **79** | T1 |

### 5.2 Aggregation Analysis

| Position | Sequence | Region | TANGO Score | Risk | Recommendation |
|----------|----------|--------|-------------|------|----------------|
| 85-92 | STSTAYMEL | FR3 | 42 | Medium | Consider T86S |
| 108-112 | DDGSY | CDR-H3 | 28 | Low | Monitor |

### 5.3 PTM Liability Sites

| Position | Motif | PTM Type | Risk | Mitigation |
|----------|-------|----------|------|------------|
| H54-55 | NG | Deamidation | High | Mutate to NQ or QG |
| H84-85 | DS | Isomerization | High | Mutate to ES or DA |
| L28 | M | Oxidation | Medium | Mutate to Leu or Ile |

### 5.4 Stability Predictions

| Variant | Predicted Tm | DTm vs Original | Tonset | Tier |
|---------|-------------|-----------------|--------|------|
| Original | 68C | - | 62C | T3 |
| Humanized_v2 | 71C | +3C | 64C | T2 |
| PTM_mitigated | 74C | +6C | 69C | T1 |

### 5.5 Expression & Manufacturing

| Variant | Titer (g/L) | Soluble Fraction | Purification | Overall |
|---------|------------|------------------|-------------|---------|
| Original | 1.2 | 75% | Good | T2 |
| Humanized_v2 | 1.8 | 85% | Excellent | T1 |
| Affinity_opt | 2.1 | 88% | Excellent | T1 |

*Source: In silico predictions, sequence analysis*
```

---

## Section 6: Immunogenicity (Phase 6)

```markdown
## 6. Immunogenicity Prediction

### 6.1 T-Cell Epitope Analysis

| Position | Peptide | MHC Alleles | IEDB Matches | Risk | Region |
|----------|---------|-------------|--------------|------|--------|
| VH 48-56 | QGLEWMGGI | HLA-DR1, DR4 | 3 | Medium | FR2 |
| VH 78-86 | TDTSTSTA | HLA-DR1 | 5 | High | FR3 |
| VL 52-60 | LLIYSASSL | HLA-DR1, DR15 | 2 | Medium | FR2 |

### 6.2 Immunogenicity Risk Score

| Variant | T-Cell Epitopes | Non-Human Residues | Agg Risk | **Total** | Category |
|---------|-----------------|-------------------|----------|-----------|----------|
| Original | 12 | 38 | High | **118** | High |
| Humanized_v1 | 5 | 13 | Medium | **60** | Medium |
| Humanized_v2 | 4 | 15 | Medium | **53** | Medium |
| Deimmunized | 2 | 10 | Low | **32** | **Low** |

### 6.3 Deimmunization Strategy

| Position | Original | Mutant | Region | Impact |
|----------|----------|--------|--------|--------|
| VH 78 | T | A | FR3 | -15 risk |
| VH 84 | T | S | FR3 | -12 risk |
| VL 55 | S | A | FR2 | -8 risk |

### 6.4 Clinical Precedent Comparison

| Antibody | Target | % ADA | Humanization |
|----------|--------|-------|--------------|
| Atezolizumab | PD-L1 | 30% | Fully human |
| Durvalumab | PD-L1 | 6% | Fully human |
| Trastuzumab | HER2 | 13% | Humanized (93%) |

*Source: IEDB, TheraSAbDab, clinical trial data*
```

---

## Section 7: Manufacturing (Phase 7)

See `MANUFACTURING.md` for detailed manufacturing content (expression, purification, formulation, CMC timeline, analytical characterization).

---

## Section 8: Final Recommendations (Phase 8)

```markdown
## 8. Final Recommendations

### 8.1 Recommended Candidate

**Variant**: VH_Humanized_Affinity_Optimized_v3

### 8.2 Key Improvements

| Metric | Original | Optimized | Improvement |
|--------|----------|-----------|-------------|
| **Humanness** | 62% | 87% | +40% |
| **Affinity (KD)** | 5.2 nM | 0.8 nM | 6.5x |
| **Developability** | 62/100 | 82/100 | +32% |
| **Immunogenicity** | High | Low | -70% |
| **Stability (Tm)** | 68C | 74C | +6C |
| **Expression** | 1.2 g/L | 2.0 g/L | +67% |

### 8.3 Experimental Validation Plan

**Phase 1: In Vitro** (3-4 months): SPR/BLI, cell binding, DSF, SEC, CHO expression, immunogenicity
**Phase 2: Lead Optimization** (2-3 months): Backup variants, formulation, scale-up
**Phase 3: Preclinical** (6-12 months): In vivo efficacy, PK/PD, tox

### 8.4 Alternative Variants (Backup)

| Variant | Profile | Recommendation |
|---------|---------|----------------|
| VH_v2 | Higher humanness (90%), lower affinity (1.8 nM) | Backup if immunogenicity issues |
| VH_v4 | Highest affinity (0.5 nM), lower developability (72/100) | Research tool only |
| VH_v1 | Balanced (2.1 nM, dev 78/100) | Second backup |

### 8.5 Next Steps

**Immediate** (Month 1-3): Gene synthesis, CHO expression, characterization
**Short-term** (Month 4-6): Stable cell line, scale-up, formulation, in vivo
**Long-term** (Month 7-24): GMP manufacturing, IND-enabling, Phase 1

---

## 9. Data Sources & Tools Used

| Tool | Purpose | Queries |
|------|---------|---------|
| IMGT | Germline identification | IGHV, IGKV genes |
| TheraSAbDab | Clinical precedents | Anti-[target] antibodies |
| AlphaFold | Structure prediction | VH-VL complex |
| IEDB | Immunogenicity | Epitope prediction |
| SAbDab | Structural analysis | PDB structures |
| UniProt | Target information | [Target accession] |
```
